Society of Interventional Radiology Position Statement: Endovascular Management Deemed An Acceptable Treatment Option for Certain Iliofemoral DVT Patients

The Society of Interventional Radiology (SIR) published a position statement deeming endovascular thrombus removal “an acceptable treatment option in selected patients with acute iliofemoral deep vein thrombosis.” The position statement was published online today on the Journal of Vascular and Interventional Radiology (JVIR) website.

SIR convened a multidisciplinary writing group that conducted a comprehensive literature review. The group used evidence from 84 studies—including randomized trials, systematic reviews and meta-analyses, prospective single-arm studies, and retrospective studies—to develop 17 recommendations to guide the use of endovascular venous intervention for the care of patients with acute iliofemoral DVT.

Among the key recommendations were for physicians to quickly identify DVT and provide prompt and adequate anticoagulation, symptom control and functional recovery at the time of diagnosis. For those with anatomically extensive and clinically severe DVT and low bleeding risk, a form of catheter directed thrombolysis (CDT) is reasonable to use in carefully selected patients after evaluating their co-morbidities and personal preferences.

“Endovascular management has been used to treat select patients with acute iliofemoral DVT for more than 25 years, but newer and better-designed studies have shown us that such interventions are most effective and safest when applied to younger patients with severe DVT symptoms,” said Suresh Vedantham, MD, FSIR, the lead author and an interventional radiologist with the Washington University in St. Louis.

“Most DVT patients will benefit from anticoagulation alone, and can be spared anything more invasive, but for those who are suffering from severe symptoms or are at the highest risk of developing lifestyle-limiting post-thrombotic syndrome, catheter-directed therapies are appropriate and effective in reducing symptom severity early and late,” said Vedantham. Vedantham was the primary investigator on the ATTRACT Trial, the findings of which were published in 2017 and informed the new recommendations. Vedantham lauded the efforts of the international thrombosis research community in conducting several pivotal randomized trials to enable well-informed guidelines, and the strong support of the SIR Foundation in the development and conduct of ATTRACT.

Based on the findings of the ATTRACT trial, the position statement authors recommend against the use of CDT for most patients with DVT that is limited to the tibial, popliteal, and femoral veins, for patients with clinical factors that confer a moderate or high risk for bleeding, and for patients with only mild lower extremity symptoms.

“Patient selection is the most important factor for success in the application of interventional treatments,” said, Kush R. Desai, MD, FSIR, chair of SIR’s Venous Disease Clinical Specialty Council, a co-author of the statement, and an interventional radiologist with Northwestern Medicine in Chicago. “Our recommendations follow the evidence so those who may benefit from endovascular treatment options are quickly identified to receive care and ensure positive outcomes.”

“Timing of intervention for acute deep vein thrombosis is important to optimize outcomes,” said Ronald S. Winokur, MD, FSIR, vice chair of SIR’s Venous Disease Clinical Specialty Council, co-author of the statement, and an interventional radiology with Weill Cornell Medicine in New York. “Clear guidance on patient selection including an understanding of extent of disease and accounting for flow dynamics helps patients receive the best treatment at the right time.”

As further research proceeds, SIR believes that adherence to the recommendations in the position statement allow for the use of endovascular therapy in a manner that optimizes benefit and minimizes harm.

“SIR is dedicated to the evidence-based practice of interventional radiology and ensuring our position statements and guidelines reflect the findings of the latest science so patients receive the best possible care,” said SIR President Parag J. Patel, MD, FSIR, an interventional radiologist with the Medical College of Wisconsin. “Thank you to the authors for their time and energy to ensure that DVT patients have access to the care appropriate for their case and medical history.”

Full statement here.

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."